{{medical}}
{{expand English}}
{{Infobox drug class
| Image = Bicalutamide.svg
| Alt = 
| Caption = {{tsl|en|Bicalutamide||Bicalutamide}}, a {{tsl|en|nonsteroidal||nonsteroidal}} antiandrogen and the most widely used [[雄激素受体|androgen receptor]] [[受体拮抗剂|antagonist]] in the treatment of [[前列腺癌|prostate cancer]].
| Width = 250px
| Synonyms = Androgen antagonists; Androgen blockers; Testosterone blockers
<!-- Class identifiers -->
| Use = [[#Medical_uses|Various]]
| ATC_prefix = L02BB
| Biological_target = [[雄激素受体|Androgen receptor]]
| Chemical_class = [[甾體|Steroid]]al; {{tsl|en|Nonsteroidal||Nonsteroidal}}
<!-- Clinical data -->
| Drugs.com = 
| Consumer_Reports = 
| medicinenet = 
| rxlist = 
<!-- External links -->
| MeshID = D000726
}}

'''抗雄激素'''（anti-androgens），或稱為'''雄性激素拮抗劑'''（androgen antagonists）。於1960年代時被發現，藉由阻斷特定的受體而抑制[[雄性激素|雄性激素]]的作用。可以競爭細胞表面的接受器或是影響雄性激素的產生。<ref name="Mowszowicz">[http://www.ncbi.nlm.nih.gov/pubmed/2530930  Mowszowicz I.（1989）. "Antiandrogens. Mechanisms and paradoxical effects". Ann Endocrinol (Paris) 50 (3): 50 (3):189–99.]，</ref>抗雄激素可用來治療一系列的疾病。在男性，抗雄激素經常用來治療[[前列腺癌|前列腺癌]]。<ref>[http://www.ncbi.nlm.nih.gov/pubmed/16845534 Mowszowicz I.（1989）. Gillatt D.（2006）. "Antiandrogen treatments in locally advanced prostate cancer: are they all the same?". J Cancer Res Clin Oncol. 1: S17-26.]</ref>对女性使用通常用來減少體內過多的雄性激素。抗雄激素對環境的影響已經受到高度的關注。許多的工業化學物質、殺蟲劑都有抗雄激素的作用。一些特定的植物也被發現會產生抗雄激素。環境中的抗雄激素對於生殖系統還在發育的小孩會有深遠的影響。

== 機轉 ==
抗雄激素可按原理分为雄性激素受體阻断剂、雄性激素合成抑制剂，和[[抗促性腺激素|抗促性腺激素]]三种。

=== 阻断受体 ===

{| class="wikitable floatright"
|+ 雄激素和抗雄激素对{{abbr|AR|雄激素受体}}的结合<ref name="pmid2788775">{{cite journal | vauthors = Ayub M, Levell MJ | title = The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5 alpha-dihydrotestosterone and [3H]cortisol binding to plasma proteins | journal = J. Steroid Biochem. | volume = 33 | issue = 2 | pages = 251–5 | date = August 1989 | pmid = 2788775 | doi = 10.1016/0022-4731(89)90301-4 | url = }}</ref><ref name="pmid14751673">{{cite journal | vauthors = Yamasaki K, Sawaki M, Noda S, Muroi T, Takakura S, Mitoma H, Sakamoto S, Nakai M, Yakabe Y | title = Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals | journal = Toxicology | volume = 195 | issue = 2-3 | pages = 177–86 | year = 2004 | pmid = 14751673 | doi = 10.1016/j.tox.2003.09.012| url = }}</ref>
|-
! 物质!! {{abbrlink|RBA|相对结合亲和度}} (%)
|-
| {{tsl|en|Metribolone||}} || 100
|-
| [[双氢睾酮|双氢睾酮]] || 85
|-
| [[醋酸环丙孕酮|醋酸环丙孕酮]] || 7.8
|-
| [[螺内酯|螺内酯]] || 2.3
|-
| {{tsl|en|Bicalutamide|比卡鲁胺}} || 1.4
|-
| {{tsl|en|Nilutamide||}} || 0.9
|-
| {{tsl|en|Hydroxyflutamide||}} || 0.57
|-
| [[氟他胺|氟他胺]] || <0.0057
|}

阻断受体的可按结果分为[[類固醇|類固醇]]類和非類固醇類两种。類固醇類抗雄激素与[[睾酮|睾酮]]、[[孕酮|孕酮]]等类固醇类似，由于其类固醇的结构经常会激活其他激素受体，造成{{tsl|en|off-target activity|偏离目标的活性}}。<ref name="LemkeWilliams2012" />因為它有高脂性，所以可以擴散穿過[[細胞膜|細胞膜]]的[[雙磷脂層|雙磷脂層]]，阻擋睪酮和[[双氢睾酮|双氢睾酮]]（DHT）鍵結到受體上，進而影響基因表現活性。<ref>[http://healthandprostate.com/prostate-cancer/steroidal-antiandrogens "Steroidal Antiandrogens"] {{webarchive|url=https://web.archive.org/web/20120426051252/http://healthandprostate.com/prostate-cancer/steroidal-antiandrogens |date=2012-04-26 }}，Health and Prostate. Retrieved 9 December 2011.</ref>[[比卡鲁胺|比卡鲁胺]]和[[氟他胺|氟他胺]]这类非類固醇類抗雄激素则没有这类副作用，因此有时候也叫“纯”抗雄激素。<ref name="LemkeWilliams2012" />

=== 抑制合成 ===
雄性激素合成抑制剂是抑制雄激素[[生物合成|生物合成]]的[[酶抑制剂|酶抑制剂]]。<ref name="FiggChau2010">{{cite book|author1=William Figg|author2=Cindy H. Chau|author3=Eric J. Small|title=Drug Management of Prostate Cancer|url=https://books.google.com/books?id=4KDrjeWA5-UC&pg=PA93|date=14 September 2010|publisher=Springer Science & Business Media|isbn=978-1-60327-829-4|pages=71–72,75,91–96}}</ref>雄激素的合成主要集中于[[性腺|性腺]]和[[肾上腺|肾上腺]]，但在[[前列腺|前列腺]]、[[毛囊|毛囊]]等位置也有发生。如[[酮康唑|酮康唑]]不只跟[[睪酮|睾酮]]還有[[双氢睾酮|双氢睾酮]]競爭雄性激素受體，還會去抑制负责将[[孕烷|孕烷]]类转换为雄激素的{{tsl|en|CYP17A1||}}的活性，从而抑制了雄性激素的合成，導致腎上腺皮質生產的睾酮量下降。<ref name="IIIBarbieri2013">{{cite book|author1=Jerome F. Strauss, III|author2=Robert L. Barbieri|title=Yen and Jaffe's Reproductive Endocrinology|url=https://books.google.com/books?id=KZ95AAAAQBAJ&pg=PA90|date=13 September 2013|publisher=Elsevier Health Sciences|isbn=978-1-4557-2758-2|pages=90–}}</ref>>由于CYP17A1还负责将[[盐皮质激素|盐皮质激素]]转换为[[糖皮质激素|糖皮质激素]]，使用这类药物时经常需要配合[[强的松|强的松]]之类的糖皮质激素，用以防止[[肾上腺功能不足|肾上腺功能不足]]。<ref name="IIIBarbieri2013" /><ref name="FiggChau2010" />[[螺内酯|螺内酯]]也是通过抑制{{tsl|en|CYP17A1||}}发挥抗雄作用。

[[5α-还原酶抑制剂|5α-还原酶抑制剂]]会抑制[[5α-还原酶|5α-还原酶]]，从而抑制[[双氢睾酮|双氢睾酮]]的合成。<ref name = Flores>{{Cite journal |vauthors=Flores E, Bratoeff E, Cabeza M, Ramirez E, Quiroz A, Heuze I | title = Steroid 5alpha-reductase inhibitors | journal = Mini-Reviews in Medicinal Chemistry | volume = 3 | pages = 225–37 |date=May 2003 | pmid = 12570838 | issue = 3 | doi=10.2174/1389557033488196}}</ref>

=== 抗促性腺激素 ===
促性腺激素，如[[黄体生成素|黄体生成素]]（LH）、[[促卵泡激素|促卵泡激素]]（FSH），负责促使性腺制造性激素。抗促性腺激素会抑制[[垂体|垂体]]在[[GnRH|GnRH]]作用下释放促性腺激素的功能。<ref name="FarmerWalker2012" />各种[[GnRH类似物|GnRH类似物]]都可以有效压制促性腺激素的产生，从而将男性的血浆雄激素含量降低95%。<ref name="FarmerWalker2012">{{cite book|author1=Peter B. Farmer|author2=John M. Walker|title=The Molecular Basis of Cancer|url=https://books.google.com/books?id=Bva8BAAAQBAJ&pg=PA232|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-1-4684-7313-1|pages=232–}}</ref>由于[[下丘脑—垂体—性腺轴|下丘脑—垂体—性腺轴]]的[[负反馈|负反馈]]调节，[[雌激素|雌激素]]、[[孕激素|孕激素]]也能有效降低促性腺激素的作用。<ref name="Brueggemeier2006" /><ref name="pmid10997774">{{cite journal |vauthors=de Lignières B, Silberstein S | title = Pharmacodynamics of oestrogens and progestogens | journal = Cephalalgia : an International Journal of Headache | volume = 20 | issue = 3 | pages = 200–7 |date=April 2000 | pmid = 10997774 | doi = 10.1046/j.1468-2982.2000.00042.x| url = http://cep.sagepub.com/cgi/pmidlookup?view=long&pmid=10997774}}</ref><ref name="pmid368741">{{cite journal | author = Neumann F | title = The physiological action of progesterone and the pharmacological effects of progestogens--a short review | journal = Postgraduate Medical Journal | volume = 54 Suppl 2 | issue = | pages = 11–24 | year = 1978 | pmid = 368741 | doi = | url = }}</ref>大剂量雌激素可以将雄激素降低到阉割水平，<ref name="pmid7000222">{{cite journal | vauthors = Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R | title = Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial | journal = Br J Urol | volume = 52 | issue = 3 | pages = 208–15 | year = 1980 | pmid = 7000222 | doi = 10.1111/j.1464-410x.1980.tb02961.x| url = }}</ref>大剂量孕激素也同样可以将男性的雄激素水平降低七到八成。<ref name="WeinKavoussi2011">{{cite book| first1 = Alan J. | last1 = Wein | first2 = Louis R. | last2 = Kavoussi | first3 = Andrew C. | last3 = Novick | first4 = Alan W. | last4 = Partin | first5 =  Craig A. | last5 = Peters | name-list-format = vanc | title = Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set|url=https://books.google.com/books?id=fu3BBwAAQBAJ&pg=PA2938|date=25 August 2011|publisher=Elsevier Health Sciences|isbn=978-1-4160-6911-9|pages=2938–}}</ref><ref name="pmid519881">{{cite journal | vauthors = Kjeld JM, Puah CM, Kaufman B, Loizou S, Vlotides J, Gwee HM, Kahn F, Sood R, Joplin GF | title = Effects of norgestrel and ethinyloestradiol ingestion on serum levels of sex hormones and gonadotrophins in men | journal = Clinical Endocrinology | volume = 11 | issue = 5 | pages = 497–504 | year = 1979 | pmid = 519881 | doi = 10.1111/j.1365-2265.1979.tb03102.x| url = }}</ref>

== 醫藥應用 ==
抗雄激素藥物可以用於一系列跟雄性激素有關的醫學問題。通常用於男性的[[前列腺癌|前列腺癌]]，[[良性前列腺增生症|良性前列腺增生症]]，[[性慾亢進|性慾亢進]]，[[男性不孕症|男性不孕症]]，還有正在進行[[激素替代疗法_(男变女)|激素替代疗法]]的[[跨性别者|跨性别者]]。

== 参见 ==
* [[雄激素|雄激素]]
* [[抗雌激素|抗雌激素]]
* [[同化類固醇|同化類固醇]]
* {{tsl|en|Androgen insensitivity syndrome||Androgen insensitivity syndrome}}
* {{tsl|en|Antiandrogens in the environment||Antiandrogens in the environment}}
* {{tsl|en|Selective androgen receptor modulator||Selective androgen receptor modulator}}

== 参考文献 ==
{{Reflist|2|refs=
<ref name="Brueggemeier2006">{{cite journal|last1=Brueggemeier|first1=Robert W.|title=Sex Hormones (Male): Analogs and Antagonists|year=2006|doi=10.1002/3527600906.mcb.200500066}}</ref>

<ref name="LemkeWilliams2012">{{cite book|author1=Thomas L. Lemke|author2=David A. Williams|title=Foye's Principles of Medicinal Chemistry|url=https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1372|date=24 January 2012|publisher=Lippincott Williams & Wilkins|isbn=978-1-60913-345-0|pages=228–231, 1371–1372}}</ref>
}}

{{Androgens and antiandrogens}}
{{Androgen receptor modulators}}
{{OCD pharmacotherapies}}

[[Category:激素剂|K]]
[[Category:抗痤疮制剂|Category:抗痤疮制剂]]
[[Category:抗雄激素物质|Category:抗雄激素物质]]
[[Category:脫毛|Category:脫毛]]
[[Category:性激素|Category:性激素]]
[[Category:跨性別與醫學|Category:跨性別與醫學]]